Differential effect of diarrhea on FK506 versus cyclosporine A trough levels and resultant prevention of allograft rejection in renal transplant recipients

American Journal of Transplantation

Volumn 2, Issue 10, 2002, Pages 989-992

  Maes, Bart D ^a   Lemahieu, Wim ^a   Kuypers, Dirk ^a   Evenepoel, Pieter ^a   Coosemans, Willy ^b   Pirenne, Jacques ^a   Vanrenterghem, Yves F Ch ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b NONE

Author keywords

Cyclosporine A; Diarrhea; FK506; Mycohphenolate mofetil

Indexed keywords

CYCLOSPORIN A; CYTOCHROME P450 3A4; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ARTICLE; CLINICAL ARTICLE; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG METABOLISM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION;

ACUTE DISEASE; CYCLOSPORINE; DIARRHEA; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL ABSORPTION; KIDNEY TRANSPLANTATION; TACROLIMUS; TIME FACTORS;

EID: 0036870921     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-6143.2002.21018.x     Document Type: Article

References (11)

1. Sollinger HW, for the US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225-232.
2. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321-1325.
3. Tricontinental Mycophenotate Mofetil Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029-1037.
4. Squifflet JP, Bäckman L, Claesson K et al. for the European Tacrolimus-MMF Renal Study Group. Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients. Transplantation 2001; 72: 63-69.
5. GhoosY, Vantrappen G. Clean collection and manipulation of stools. Lancet 1977; i: 884-885.
6. Frühwirth M, Fischer H, Simma B, Ellemunter H. Rotavirus infection as cause of tacrolimus elevation in solid-organ-transplanted children. Pediatr Transplant 2001; 5: 88-92.
7. Matsui A, Arakawa Y, Momoya T, Sasaki N, Kawasaki S, Tanaka K. Apparently increased trough levels of tacrolimus caused by acute infantile diarrhea in two infants with biliary atresia after liver transplantation. Acta Paediatr Jpn 1996; 38: 699-701.
8. Eades SK, Boineau FG, Christensen ML. Increased tacrolimus levels in a pediatric renal transplant patient attributed to chronic diarrhea. Pediatr Transplant 2000; 4: 63-66.
9. Hochleitner BW, Bösmüller C, Nehoda H et al. Increased tacrolimus levels during diarrhea. Transpl Int 2001; 14: 230-233.
10. Mittal N, Thompson JF, Kato T, Tzakis AG. Tacrolimus and diarrhea: pathogenesis of altered metabolism. Pediatr Transplant 2001; 5: 75-79.
11. Tuteja S, Alloway RR, Johnson JA, Gaber AO. The effect of gut metabolism on tacrotimus bioavailability in renal transplant recipients. Transplantation 2001; 71: 1303-1307.